Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of sugarcane bagasse fibre on the flexural behavior of geopolymer concrete RCC beams

Autor: Chandana Srimanthula, Srinivas T., Ramana Rao N V

Publikováno v: E3S Web of Conferences, Vol 309, p 01113 (2021)

CO2 is released into the atmosphere during the manufacture of Ordinary Portland Cement (OPC). Fly ash, a by-product of the coal industry, is used to replace OPC in concrete. It contains a lot of silicate gel and is mixed with an alkaline solution to

Externí odkaz: https://doaj.org/article/d4c8fbc3c5df4005a5969cd8b85181f7

An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature

Autor: Conley Barbara A, Minter Rebecca M, Kotaru Veera-Pavan, Cuison Reuben V, Makol Ashima, Efeovbokhan Nephertiti, Chandana Sreenivasa R

Publikováno v: Journal of Medical Case Reports, Vol 5, Iss 1, p 253 (2011)

Abstract Background Autoimmune pancreatitis is a rare chronic inflammatory pancreatic disease that is increasingly being diagnosed worldwide. As a result of overlap in clinical and radiological features, it is often misdiagnosed as pancreatic cancer.

Externí odkaz: https://doaj.org/article/b75b05bb9e3941209702d09388635148

Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.

Autor: Botta GP; Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA 92037, United States., Abdelrahim M; Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, United States., Drengler RL; Medical Oncology, The START Center for Cancer Care, San Antonio, TX 78229, United States., Aushev VN; Oncology, Natera, Inc., Austin, TX 78753, United States., Esmail A; Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, United States., Laliotis G; Oncology, Natera, Inc., Austin, TX 78753, United States., Brewer CM; Oncology, Natera, Inc., Austin, TX 78753, United States., George GV; Oncology, Natera, Inc., Austin, TX 78753, United States., Abbate SM; Medical Oncology, The START Center for Cancer Care, San Antonio, TX 78229, United States., Chandana SR; Department of Gastrointestinal Medical Oncology, Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI 49546, United States., Tejani MA; Hematology and Oncology, Advent Health Cancer Institute, Orlando, FL 32804, United States., Malla M; Section of Hematology and Oncology, University of Alabama at Birmingham, AL 35233,United States., Bansal D; Department of Hematology-Oncology, Saint Luke's Cancer Institute, Kansas City, MO 64111, United States., Rivero-Hinojosa S; Oncology, Natera, Inc., Austin, TX 78753, United States., Spickard E; Oncology, Natera, Inc., Austin, TX 78753, United States., McCormick N; Oncology, Natera, Inc., Austin, TX 78753, United States., Cecchini M; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT 06520, United States., Lacy J; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT 06520, United States., Fei N; Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, United States., Kasi PM; Division of Internal Medicine, Department of Oncology/Hematology, Weill Cornell Medicine, New York, NY 10021, United States., Kasi A; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, KS 66160, United States., Dayyani F; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, United States., Hanna DL; Division of Medical Oncology, Norris Cancer Center, Keck Medicine of USC, Los Angeles, CA 90033, United States., Sharma S; Oncology, Natera, Inc., Austin, TX 78753, United States., Malhotra M; Oncology, Natera, Inc., Austin, TX 78753, United States., Aleshin A; Oncology, Natera, Inc., Austin, TX 78753, United States., Liu MC; Oncology, Natera, Inc., Austin, TX 78753, United States., Jurdi A; Oncology, Natera, Inc., Austin, TX 78753, United States.

Publikováno v: The oncologist [Oncologist] 2024 Oct 03; Vol. 29 (10), pp. 859-869.

Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report.

Autor: Chandana SR; The Cancer and Hematology Centers, Grand Rapids, MI, USA.; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, USA., Frisch A; College of Human Medicine, Michigan State University, Grand Rapids, MI, USA., Mendoza S; College of Human Medicine, Michigan State University, Grand Rapids, MI, USA., Sinniah RS; College of Human Medicine, Michigan State University, Grand Rapids, MI, USA., Crysler O; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA., Banga R; Renal Associates of West Michigan, Grand Rapids, MI, USA., Perkins DE; Department of Pathology, Spectrum Health, Grand Rapids, MI, USA.

Publikováno v: Journal of gastrointestinal oncology [J Gastrointest Oncol] 2024 Feb 29; Vol. 15 (1), pp. 478-484. Date of Electronic Publication: 2024 Feb 01.